166 related articles for article (PubMed ID: 20228780)
1. Foveolar type dysplasia in Barrett esophagus.
Brown IS; Whiteman DC; Lauwers GY
Mod Pathol; 2010 Jun; 23(6):834-43. PubMed ID: 20228780
[TBL] [Abstract][Full Text] [Related]
2. Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus?
Khor TS; Alfaro EE; Ooi EM; Li Y; Srivastava A; Fujita H; Park Y; Kumarasinghe MP; Lauwers GY
Am J Surg Pathol; 2012 Mar; 36(3):331-42. PubMed ID: 22261707
[TBL] [Abstract][Full Text] [Related]
3. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
4. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
Asthana N; Mandich D; Ligato S
Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
[TBL] [Abstract][Full Text] [Related]
5. Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia.
Park DY; Srivastava A; Kim GH; Mino-Kenudson M; Deshpande V; Zukerberg LR; Song GA; Lauwers GY
Am J Surg Pathol; 2008 Apr; 32(4):524-33. PubMed ID: 18300795
[TBL] [Abstract][Full Text] [Related]
6. Esophageal dysplasia and adenocarcinoma: a study with double immunostaining for intestinal and gastric markers.
Chlumská A; Mukenšnabl P; Waloschek T; Zámečník M
Cesk Patol; 2018; 54(2):81-85. PubMed ID: 30441967
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic differences between esophageal and gastric intestinal metaplasia.
Piazuelo MB; Haque S; Delgado A; Du JX; Rodriguez F; Correa P
Mod Pathol; 2004 Jan; 17(1):62-74. PubMed ID: 14631367
[TBL] [Abstract][Full Text] [Related]
8. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
9. Barrett esophagus: diagnostic challenges.
Hagen CE; Lauwers GY; Mino-Kenudson M
Semin Diagn Pathol; 2014 Mar; 31(2):100-13. PubMed ID: 24815936
[TBL] [Abstract][Full Text] [Related]
10. Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.
Burjonrappa SC; Reddimasu S; Nawaz Z; Gao X; Sharma P; Loggie B
Indian J Cancer; 2007; 44(1):1-5. PubMed ID: 17401217
[TBL] [Abstract][Full Text] [Related]
11. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance.
Park DY; Srivastava A; Kim GH; Mino-Kenudson M; Deshpande V; Zukerberg LR; Song GA; Lauwers GY
Mod Pathol; 2010 Jan; 23(1):54-61. PubMed ID: 19820687
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Hayes S; Ahmed S; Clark P
J Clin Pathol; 2011 Feb; 64(2):110-3. PubMed ID: 21106545
[TBL] [Abstract][Full Text] [Related]
13. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
14. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
[TBL] [Abstract][Full Text] [Related]
15. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
16. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
[TBL] [Abstract][Full Text] [Related]
17. Intestinal metaplasia of the stomach and esophagus: an immunohistochemical study of 60 cases including comparison with normal and inflamed intestinal mucosa.
Chlumská A; Mukenšnabl P; Mareček P; Zámečník M
Cesk Patol; 2014 Jul; 50(3):141-8. PubMed ID: 25186595
[TBL] [Abstract][Full Text] [Related]
18. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
19. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
20. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma.
Demicco EG; Farris AB; Baba Y; Agbor-Etang B; Bergethon K; Mandal R; Daives D; Fukuoka J; Shimizu M; Dias-Santagata D; Ogino S; Iafrate AJ; Gaissert HA; Mino-Kenudson M
Mod Pathol; 2011 Sep; 24(9):1177-90. PubMed ID: 21572404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
